1	Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial
2	revascularization.
3	
4	Short Title: Apo(a) size and peripheral revascularization
5	
6	Marianna Pavlyha <sup>1</sup> , Madeleine Hunter <sup>2</sup> , Roman Nowygrod <sup>2</sup> , Virenda Patel <sup>2</sup> , Nicholas
7	Morrissey <sup>2</sup> , Danielle Bajakian <sup>2</sup> , Yihao Li <sup>1</sup> , Gissette Reyes-Soffer <sup>1</sup>
8	
9	<sup>1</sup> Department of Medicine, Division of Preventive Medicine and Nutrition, Columbia University
10	Vagelos College of Physicians and Surgeons, New York, NY
11	<sup>2</sup> Department of Surgery, Division of Vascular Surgery, Columbia University Vagelos College of
12	Physicians and Surgeons, New York, NY
13	
14	Corresponding Author:
15	
16	Gissette Reyes-Soffer
17	630 West 168th street
18	P&S 10th floor, room 501
19	New York, NY 10032
20	Office: (212) 305-9298
21	gr2104@cumc.columbia.edu
22	
23	The authors have no competing interest

## 1 ARTICLE HIGHLIGHTS

## 2 **Type of Research:**

- 3 Single-center prospective cohort study
- 4

## 5 Key Findings:

- 6 25 subjects with symptomatic PAD underwent open or
- 7 endovascular lower extremity revascularization in a small
- 8 cohort. Smaller apo(a) isoforms were associated with
- 9 occlusion of the treated lesion(s) within 2-4 weeks
- 10 [OR=1.97 (95% CI 1.01 3.86, p<0.05)], suggesting
- 11 apo(a) isoform size as a predictor of primary patency in
- 12 the early period after lower extremity intervention.
- 13

#### 14 Take Home Message:

- 15 Subjects with high Lp(a) levels, generally have smaller
- 16 apo(a) isoform sizes. We find that, in this small cohort,
- 17 patients undergoing peripheral arterial revascularization
- 18 subjects with small isoforms are at an increased risk of
- 19 treated vessel occlusion in the perioperative period.

20

## 21 <u>Table of Contents Summary</u>

- 22 Subjects with symptomatic PAD requiring lower
- 23 extremity revascularization have high median Lp(a)

1	levels. Individuals with smaller apo(a) weighted isoform
2	size (wIS) have lower primary patency rates and/or
3	require re-intervention.
4	
5	Key Words: peripheral arterial disease, lipids, Lipoprotein(a), apo(a), isoforms
6	
7	Abstract
8	Background: High lipoprotein (a) [Lp(a)] is associated with adverse limb events in patients
9	undergoing lower extremity revascularization. Lp(a) levels are genetically pre-determined, with
10	LPA gene encoding for two apolipoprotein (a) [apo(a)] isoforms. Isoform size variations are
11	driven by the number of kringle IV type 2 (KIV-2) repeats. Lp(a) levels are inversely correlated
12	with isoform size. In this study, we examined the role of Lp(a) levels, apo(a) size and
13	inflammatory markers with lower extremity revascularization outcomes.
14	
15	Methods: 25 subjects with chronic peripheral arterial disease (PAD), underwent open or
16	endovascular lower extremity revascularization (mean age of 66.7±9.7 years; F=12, M=13;
17	Black=8, Hispanic=5, and White=12). Pre- and post-operative medical history, self-reported
18	symptoms, ankle brachial indices (ABIs), and lower extremity duplex ultrasounds were obtained.
19	Plasma Lp(a), apoB100, lipid panel, and pro-inflammatory markers (IL-6, IL-18, hs-CRP, TNFα)
20	were assayed preoperatively. Isoform size was estimated using gel electrophoresis and weighted
21	isoform size (wIS) calculated based on % isoform expression. Firth logistic regression was used
22	to examine the relationship between Lp(a) levels, and wIS with procedural outcomes: symptoms

4

1	(better/worse), primary patency at 2-4 weeks, ABIs, and re-intervention within 3-6 months. We	
2	controlled for age, sex, history of diabetes, smoking, statin, antiplatelet and anticoagulation use.	
3		
4	Results: Median plasma Lp(a) level was 108 (44, 301) nmol/L. The mean apoB100 level was	
5	$168.0 \pm 65.8$ mg/dL. These values were not statistically different among races. We found no	
6	association between Lp(a) levels and wIS with measured plasma pro-inflammatory markers.	
7	However, smaller apo(a) wIS was associated with occlusion of the treated lesion(s) in the	
8	postoperative period [OR=1.97 (95% CI 1.01 - 3.86, p<0.05)]. The relationship of smaller apo(	
9	wIS with re-intervention was not as strong [OR=1.57 (95% CI 0.96 - 2.56), p=0.07]. We	
10	observed no association between wIS with patient reported symptoms or change in ABIs.	
11		
12	Conclusions: In this small study, subjects with smaller apo(a) isoform size undergoing peripheral	
13	arterial revascularization were more likely to experience occlusion in the perioperative period	
14	and/or require re-intervention. Larger cohort studies identifying the mechanism and validating	
15	these preliminary data are needed to improve understanding of long-term peripheral vascular	
16	outcomes.	
17		
18	Introduction	
19	Lipoprotein (a) [Lp(a)] is causal for the development of atherosclerotic cardiovascular disease	
20	(ASCVD) and atherothrombosis as shown in epidemiological, Mendelian Randomization, and	
21	genome wide association studies (GWAS) <sup>1</sup> . Elevated Lp(a) levels are independently associated	
22	with incidence of major adverse cardiovascular events (MACE) and major adverse limb events	

(MALE) after lower extremity endovascular<sup>2</sup> or open surgery<sup>3</sup> while controlling for other risk

5

1 factors. Despite this, measurement of Lp(a) levels is not standard of care in those undergoing 2 vascular intervention. Lp(a) particles contain two main apolipoproteins: B100 [apoB100] and 3 apolipoprotein(a) [apo(a)]. Individuals can express one or two apo(a) isoforms and these vary in 4 size depending on the number of Kringle-IV type 2 (KIV-2) repeats that are encoded by the LPA 5 gene. Plasma Lp(a) levels and apo(a) isoform size are inversely correlated, with smaller isoforms generally dominating<sup>1</sup>. There are well described mechanisms linking high levels of 6 7 Lp(a) and atherosclerosis, including complement activation, inflammatory, and coagulation pathways<sup>1</sup>. Apo(a) can potentiate atherothrombosis through presence of lysine binding sites that 8 9 allow accumulation of lipid in the arterial wall and activation of inflammatory pathways, owning to its binding of oxidized phospholipids (OxPL)<sup>45</sup>. High Lp(a) levels have also been 10 11 association with enhanced expression of adhesion molecules in endothelial cells and proinflammatory interleukins in monocytes and macrophages  $^{6}$ . Finally, apo(a) has evolved from 12 the plasminogen gene through duplication and remodeling  $^{7}$  and its homology with plasminogen 13 14 allows it to compete for its binding site, inhibiting thrombolysis and indirectly promoting a 15 prothrombotic state. These mechanisms are of interest in vascular patency. 16 Numerous studies show that high Lp(a) levels are associated with increased incidence of 17 18 claudication, symptoms progression, re-stenosis after intervention, hospitalization, and limb amputation<sup>8</sup>, and those with high Lp(a) have a higher risk of combined PAD outcomes after 19 20 adjusting for other traditional risk-factors. Few studies, however, have looked at the association 21 between apo(a) isoform size and peripheral arterial surgical outcomes. Available data suggests

that both increased Lp(a) levels and the presence of small apo(a) isoforms are associated with the

23 increased incidence of symptomatic PAD  $^{9 \ 10}$ . Whereas small apo(a) isoforms were shown to be

6

1	independently associated with three-fold increase in risk of major adverse cardiovascular events	
2	after coronary artery bypass grafting (CABG) at long term follow up <sup>11</sup> , the role of this Lp(a)	
3	component on lower limb outcomes have not been explored. In view of previous findings and	
4	needs in the field, we developed a study using available stored plasma samples and outcomes	
5	data on subjects with PAD who underwent lower extremity revascularization, yet they had no	
6	history of Lp(a) measurement. We examined the relationships between apo(a) isoform size,	
7	primary patency, and rate of re-intervention. In addition, given apo(a)'s role in propagating the	
8	inflammatory cascade implicated in atherosclerotic plaque formation <sup>12 13 14</sup> , the relationship of	
9	pro-inflammatory markers (IL-6, IL-18, hs-CRP, TNF $\alpha$ ) with apo(a) size and surgical outcomes	
10	were investigated.	
11		
12	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase	
12 13	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased	
12 13 14	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that	
12 13 14 15	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that can be used to design larger studies in patients with advanced PAD. These studies may assist	
12 13 14 15 16	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that can be used to design larger studies in patients with advanced PAD. These studies may assist with improving risk prediction, stratification, and medical optimization of surgical patients with	
12 13 14 15 16 17	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that can be used to design larger studies in patients with advanced PAD. These studies may assist with improving risk prediction, stratification, and medical optimization of surgical patients with high Lp(a).	
12 13 14 15 16 17 18	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that can be used to design larger studies in patients with advanced PAD. These studies may assist with improving risk prediction, stratification, and medical optimization of surgical patients with high Lp(a).	
12 13 14 15 16 17 18 19	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that can be used to design larger studies in patients with advanced PAD. These studies may assist with improving risk prediction, stratification, and medical optimization of surgical patients with high Lp(a).	
12 13 14 15 16 17 18 19 20	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that can be used to design larger studies in patients with advanced PAD. These studies may assist with improving risk prediction, stratification, and medical optimization of surgical patients with high Lp(a).	
12 13 14 15 16 17 18 19 20 21	There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase 3 of development <sup>15</sup> , highlighting the need to understand which populations are at increased disease risk and would benefit from treatment. Our small study provides preliminary insights that can be used to design larger studies in patients with advanced PAD. These studies may assist with improving risk prediction, stratification, and medical optimization of surgical patients with high Lp(a). <b>Methods</b> We analyzed data from all 27 participants recruited from the Columbia University Irving Medical Center (CUIMC) Vascular Surgery Clinic into a prospective cohort study	

23 (ABALEAR)] between June 2018 and March 2021, **Supplemental Figure 2**. The study protocol

7

was approved by the CUIMC Institutional Review Board (AAAL7756). Inclusion criteria
encompassed adult subjects with a clinical diagnosis of PAD, who were planned to undergo nonemergent revascularization (open or endovascular) of the affected lower extremity. Those with
ischemic wounds, active infectious process, or cardiovascular intervention within 12 months of
enrollment were excluded. Two of the participants who underwent only diagnostic angiogram
were also excluded from final analysis. The type of intervention was at the discretion of the
treating provider.

8

9 Recruitment/Enrollment: Subjects that met inclusion and exclusion criteria were contacted prior 10 to their scheduled operation and informed consent was obtained. Medical and social history were collected by a licensed health professional, including demographic information (age, sex, self-11 reported race-ethnicity (SRRE)), history of smoking, hypertension (HTN), diabetes, carotid 12 13 artery disease (CAD) or dyslipidemia. Medication use [antihypertensives, statins, antiplatelet 14 (AP), direct oral anticoagulant (DOAC)] and symptoms of rest pain or claudication (ambulatory 15 distance in city blocks) were recorded. A pre-operative physical exam was performed, which 16 included distal pulses, a lower extremity arterial duplex ultrasound (US), ankle brachial index 17 (ABI), and body mass index (BMI). On the day of the surgical procedure, arterial blood samples 18 were collected using EDTA tubes; plasma was separated and stored at -80 °C.

19

Study Follow-up (2-4 weeks and 3-6 months): Participants were seen in the office for their postoperative visits by their respective providers. During these visits, physical exam (pulses, US,
ABIs) to assess for primary patency and the trajectory of self-reported subjective symptoms were
determined based on presence or resolution of rest pain and changes in walking distance. These

8

1	were then categorized as 'improved,' 'worsened' or 'stayed the same.' In cases of multiple
2	vessels intervention, absent blood flow in the most proximal intervened vessel constituted
3	occlusion. If multiple vessels below the popliteal artery trifurcation were intervened on,
4	multiphasic in-line flow preserved in at least one of the vessels constituted patency. Palpable
5	pulses over the graft and distally constituted patency. Two subjects did not have a complete US
6	assessment at first follow-up and were excluded from sub-analysis. Change in ABI <sup>16</sup>
7	measurements were categorized as improved from pre-operative measurement vs not improved
8	(worsened or the same). Of note, ABI measurements falsely elevated due to calcified non-
9	compressible vessels, incomplete, or missing for at least one of the visits were excluded from the
10	sub-analysis. Hence, the available ABI data is limited. Toe pressures were not available on this
11	cohort. In addition to the above, the 3-6 months visit included records of any interval
12	interventions on the ipsilateral extremity.

13

14 Plasma Lp(a), apoB100, lipids [triglycerides (TG), total cholesterol(C), high density lipoprotein 15 (HDL)] were automatically measured on Integra 400 plus (Roche). Plasma LDL-C levels were calculated using the Friedewald formula (one subject had a TG level >400mg/dL and was not 16 reported). Plasma apoB100 levels were measured by a human enzyme-linked immunosorbent 17 18 assay (ELISA) from Mabtech, Inc, Cincinnati, OH. Lp(a) plasma concentration were measured 19 using the isoform-independent sandwich ELISA developed by the Northwest Lipid Metabolism 20 and Diabetes Research Laboratory at Medpace, Inc. Apo(a) isoform size measurements were 21 performed by the same laboratory using agarose gel electrophoresis. ChemiDoc MP Imaging 22 System was used to determine the isoforms using in-house standards and relative expression of 23 each isoform was reported. Weighted isoform size (wIS) was calculated using the % isoform

1	expression (two isoform masses were multiplied by their relative expression). Pro-inflammatory
2	markers Interleukin-6 (IL6), Interleukin-18 (IL-18) were measured using ELISA kits (D6050,
3	R&D Systems, Minneapolis, MN) and (DY318-05, R&D Systems, Minneapolis, MN),
4	respectively. High sensitivity C-reactive protein (hs-CRP) and Tumor Necrosis Factor alpha
5	(TNF $\alpha$ ) were measured on an Integra400plus (Roche) using standardized methods at the Irving
6	Institute for Clinical and Translational Research Biomarkers laboratory at CUIMC.
7	
8	Statistical Analysis
9	All data were analyzed using standard R software (Version 4.2.2). Normally distributed variables
10	were summarized by means and standard deviations (SD). Lp(a) levels and TGs were
11	summarized by median and interquartile range. The relationship of $Lp(a)$ levels with wIS in the
12	three SRRE groups was studied by Analysis of Variance (ANOVA). Racial differences in Lp(a)
13	levels and wIS were assessed using the median test. Due to small samples size, an
14	implementation based on the Firth logistic regression <sup>17</sup> was chosen to examine the relationship
15	between wIS with procedural outcomes: change in symptoms, primary patency of treated
16	lesion(s), change in ABIs, and re-intervention within 3-6 months. Results were reported as odds
17	ratios (OR). Sex, age, smoking status, history of diabetes, statin, antiplatelet and DOAC use were
18	considered as potential confounders, according to the literature, and were included in the
19	regression <sup>18</sup> <sup>19</sup> <sup>20</sup> <sup>21</sup> . HTN and BMI were not integrated into the model based on their role in
20	published studies of surgical outcomes <sup>22 23</sup> . We did not control for history of CAD, as literature
21	shows that most individuals with diagnosis of PAD have some degree of CAD and at least 60%
22	have significant CAD <sup>24.</sup> .

10

## 1 Results

2 Baseline Characteristics: Subject demographics, lipid and lipoprotein levels are shown in **Table** 3 I. The study population included 12 females and 13 males with a mean age of  $66.7\pm9.7$  years. 4 Our cohort was multiethnic with 8 Blacks, 5 Hispanics, and 12 Whites, representative of the 5 available population at our institution. All subjects were Rutherford stage 3 and 4.5 subjects 6 underwent open revascularization and 20, endovascular. Majority of the subjects underwent 7 infra-inguinal intervention (N=23) and 6 required re-intervention within 3-6 months. Individuals 8 were mildly overweight and lipid levels consistent with a population being treated for 9 dyslipidemia. Despite use of lipid lowering therapies, the mean apoB100 levels were  $168.0 \pm$ 10 65.8 mg/dL. Median plasma Lp(a) level was 108 (44, 301) nmol/L. Primary patency rates at 2-4 11 weeks and 3-6 months were 76% and 68%. Rate of re-intervention measured at 3-6-months visit 12 was 24%.

13

Lp(a) levels and Isoform Size: Previous reports show that high Lp(a) levels are associated with worse outcomes after surgical intervention. We found that most of the individuals in our cohort had high Lp(a) levels. The mean *wIS* was  $18.4 \pm 4.1$  and as expected, there was an inverse relationship between Lp(a) levels and *wIS* ( $\mathbb{R}^2 = 0.20$ ; p=0.02), Figure 1. Most individuals express two apo(a) isoforms, however in our small diverse cohort, we found that half (N=12) individuals expressed only a single isoform, **Supplemental Table I**, with predominance of the small isoform, Figure 2.

21

*Relationship of Lp(a) levels and Isoforms with surgical outcomes:* We did not find significant
associations between Lp(a) levels and post-surgical symptoms, ABI, primary patency, or re-

1	intervention, Table IIb. Surgery type did not affect this result. However, wIS was significantly
2	correlated with primary patency at 2-4 weeks [OR=1.97 (95% CI 1.01 - 3.86, p<0.05)], Table
3	IIa. Controlling for SRRE did not change these study outcomes. We observed a trend between
4	wIS and re-intervention in the 3-6 months period [OR=1.57 (95% CI 0.96 - 2.56), p=0.07)].
5	When we used predominant apo(a) isoform size as the primary variable in our model, and
6	adjusted for plasma Lp(a) levels, our observed effect of apo(a) size on primary patency remained
7	statistically significant [OR=2.01, (CI 1.03 - 3.93) p<0.05], suggesting that apo(a) was a stronger
8	a predictor of outcomes compared to Lp(a) levels in this cohort.
9	
10	The type of surgical procedure could have affected our study outcomes, however when we
11	assessed the relationship between wIS isoform size and primary patency for subjects that only
12	underwent endovascular intervention, we noted a similar trend [OR=1.67 (95% CI 0.95 - 2.94),
13	p=0.08]. We did not see an association between wIS and patient reported symptoms or change in
14	ABIs at 3-6 months. It is notable, however, that our sample size for analysis of ABIs was much
15	smaller (N=14) due to inability of all subjects to undergo the test reliably (ex. pain, non-
16	compliant calcified vessels resulting in falsely elevated results) or missing measurement from
17	some visits.
18	
19	As expected, inflammatory markers IL-18 and hs-CRP were higher in this cohort when
20	compared to published levels in healthy cohorts, Table III. However, we found no significant
21	relationship between plasma Lp(a) levels or $wIS$ with IL-6, IL-18, hs-CRP, or TNF $\alpha$ .
22	Additionally, inflammatory markers were not associated with our surgical outcomes.

- 23
- 24

# 1 Discussion

High Lp(a) levels are associated with adverse limb events in patients with symptomatic PAD 2 undergoing lower extremity revascularization <sup>25 26 2</sup>. International guidelines (Canadian <sup>27</sup> and 3 ECC  $^{28}$ ) advocate for all individuals to have Lp(a) measured once in a lifetime. In the United 4 States, the American Heart Association (AHA) suggest using Lp(a) levels as a 'risk enhancer'<sup>29</sup>. 5 6 However, there are no specific guidelines for Lp(a) measurements in patients with advanced 7 PAD that are referred for surgical intervention. All subjects in our study have been diagnosed 8 with at least one metabolic disease, however, they were not screened for Lp(a) by their primary 9 providers; and the majority were found to have elevated levels. 10 Although our study sample is small, which limits the generalizability of the results, it features a 11 12 good representation based on gender and race. These data can be used to develop well controlled 13 cross-sectional studies that can examine the role of apo(a) in larger populations with PAD. Most 14 individuals at risk or that have ASCVD, obtain laboratory measurement of low-density 15 lipoprotein cholesterol (LDL-C), an apoB100 containing particle. Physicians rely on these measurements for prescribing lipid therapies, such as statins, in clinical practice. We observed 16 that in our cohort, 76% of individuals were prescribed statins. While statins significantly lower 17 LDL-C, they tend to increase Lp(a) by about 11%<sup>1</sup>. It is important to note, however, that the 18 laboratory levels of LDL-C in plasma are known to be confounded by the presence of  $Lp(a)-C^{30}$ , 19 20 which contains both apoB100 and apo(a). The reason for this overlap lies in similar plasma 21 densities between Lp(a) and LDL particles. Thus, in patients with high levels of Lp(a) the actual 22 LDL-C is lower from the reported value and some investigators believe apoB100 to be a more accurate measure of cardiovascular risk compared to  $LDL-C^{31}$ . This is important, because most 23

1	vascular patients are prescribed statins, which works via increased LDL receptor expression,
2	facilitating clearance of LDL-C, but not Lp(a). Patients that have elevated LDL-C while on
3	optimal LDL lowering therapy would benefit from having their Lp(a) measured and treated, as
4	there is a high probability that the increased cholesterol is carried by Lp(a) particles. We observe
5	this in some patients in our population as well and this may explain why some patients, despite
6	LDL-C lowering by statins, remain at risk <sup>32</sup> . Two out of 19 subjects in the study who were taking
7	statins had above normal LDL-C levels; both had Lp(a) measurements > 200 nmol/L. In this
8	population where Lp(a) is high, this particle may carry most of the cholesterol.
9	
10	Whereas there has been great interest in Lp(a) levels and surgical outcomes, few studies have
11	looked at the role of apo(a) size in vascular surgery, and specifically, there are no existing reports
12	on patency after lower extremity revascularization. The LPA gene encodes for two apo(a)
13	isoforms that comprise the Lp(a) particle. Variations in size of the apo(a) isoforms are driven by
14	the number of KIV-2 repeats. Small number of KIV-2 repeats lead to small apo(a) size and are
15	associated with higher Lp(a) levels, posing an increased risk for cardiovascular disease,
16	including PAD <sup>9</sup> . Similar to other cohorts <sup>1</sup> , the current study finds an inverse association
17	between plasma Lp(a) levels and apo(a) allele size, with smaller isoforms associated with higher
18	Lp(a) levels <sup>33</sup> . Whereas ~20% of the general population is expected to have high $Lp(a)$ and
19	express two apo(a) isoforms <sup>1</sup> , close to half of our subjects with high median Lp(a) expressed
20	only one isoform size, Supplemental Table I. Previous studies in individuals with PAD showed
21	that both increased Lp(a) serum concentrations (75th percentile) and the small apo(a) phenotype
22	are strongly associated with symptomatic PAD, independent of other confounders <sup>9</sup> . We did not
23	see any significant correlation between Lp(a) levels and outcomes, but when controlled for Lp(a)

14

1 levels, the predictive association of *wIS* with primary patency was still statistically significant. 2 Although data in the literature regarding disease predictability of Lp(a) vs apo(a) is conflicting, 3 there is evidence that the strength of the association is higher for apo(a) isoform size in certain diseases<sup>34</sup>. To our knowledge, there are no reports assessing the correlation between apo(a) size 4 and primary patency. Our preliminary study finds that small apo(a) size strongly correlates with 5 primary patency within 2-4 weeks with a trend towards a higher rate or re-intervention at 3-6 6 7 months. Although more comprehensive evaluation of the prognostic relationship between apo(a)8 size and these outcomes of peripheral arterial interventions would be served in a randomized or 9 cross-sectional study, these results support what is already known about apo(a)'s mode of action. 10 We postulate that the probable mechanisms lie in the apo(a)'s kringle structure having homology 11 with fibrinolytic proenzyme plasminogen, but inactive in fibrinolysis. Small apo(a) isoform size 12 resulting from low LPA KIV-2 number of repeats can slow fibrinolysis and thus indirectly 13 promote thrombosis, leading to increased risk of perioperative complications such as graft occlusion or thromboembolic events <sup>35</sup>. Additionally, apo(a) potentiates thrombosis by binding 14 and inactivating tissue factor pathway inhibitor (TFPI)<sup>36</sup>. This is especially important, as many 15 of peripheral arterial intervention are performed to aid in wound healing and this period may be 16 imperative for patients with tissue loss. These pro-thrombotic action of the apo(a) could also 17 18 explain the high rate of early re-intervention in this cohort of patients with high Lp(a), particularly as 5 our 6 subjects in the group requiring re-intervention had small apo(a), 19 Supplemental Figure 1. 20 21 22 A study from a UK biobank studied approximately 460 thousand participants and showed

23 significant differences in Lp(a) concentrations across racial subgroups, specifically with higher

1	Lp(a) levels seen within South Asian and Black population compared to Whites <sup>37</sup> . Although on
2	average Hispanics had higher values than Whites in our cohort, there we no statistically
3	significant differences in Lp(a) values and apo(a) size among different races and race had no
4	impact on most surgical outcomes. This could be due to our limited sample size.
5	
6	Some of Lp(a)'s role in disease risk has been linked to inflammatory profiles. Specifically,
7	elevated TNF- $\alpha$ , IL-6, and CRP levels <sup>12,38</sup> at baseline correlate with worse vascular outcomes in
8	patients with diabetes, PAD, and chronic limb-threatening ischemia undergoing endovascular
9	procedures <sup>14</sup> . We did not find any significant correlations with circulating inflammatory markers
10	and Lp(a), wIS or surgical outcomes, however, we did not measure OxPLs which may add new
11	information in PAD patients as it has in other described populations <sup>39</sup> . Of note, it has also been
12	reported that statins decreased the serum levels of hs-CRP <sup>12</sup> and downregulate IL-6 <sup>13</sup> . Majority
13	of our subject were taking high-dose statins (which also tend to increase Lp(a)) and may be
14	contributing to our observations.
15	
16	Although there are no currently available targeted therapies to treat high Lp(a), some agents
17	available in the United States that lower apoB100 and LDL-C also decrease Lp(a) modestly,
18	such as niacin, Ezetimibe, and PSCK9 inhibitors. The FDA has also recently approved
19	lipoprotein apheresis for high-risk cases with $Lp(a) > 60 \text{ mg/dL}$ and $LDL-C > 100 \text{ mg/dL}$ and with
20	either documented CAD or PAD <sup>1</sup> . The two apo(a) targeted therapies, antisense oligonucleotides
21	and siRNA and are also in phase 3 studies are expected to report their initial results in 2024.
22	While we wait for this data, new studies now suggest the benefit of DAPT in patients with high
23	Lp(a) <sup>40</sup> . Particularly, recent outcomes in these patients undergoing percutaneous coronary

16

1	intervention (PCI), showed that prolonged DAPT (>1 year) reduced ischemic cardiovascular
2	events, all-cause mortality, cardiac mortality, and definite/probable stent thrombosis, without
3	increase in clinically relevant bleeding risk compared with $\leq$ 1-year DAPT <sup>41</sup> . Data from this
4	small study cohort raise the question whether we need to rethink risk assessment and post-
5	operative management in patients high Lp(a) and small apo(a) size undergoing lower extremity
6	interventions. As the importance of Lp(a) becomes more recognized in clinical practice <sup>37,42</sup> , and
7	we review cardiovascular outcome data from phase 3 apo(a) targeted treatments, developing
8	larger studies that have more stringent control of patient selection and type of intervention would
9	serve as the next step in validating the generalizability of the current findings.
10	
11	Understanding the impact of apo(a) isoform size on Lp(a) levels and surgical outcomes may
12	guide risk stratification and therapeutic decision-making when it comes to pre-operative
13	optimization and medical management post-operatively. Lp(a) levels are stable throughout
14	lifetime. Although measuring apo(a) size may not be feasible in all patients and it currently not
15	used in clinical practice, as genetic testing becomes more widely available, assessing KIV-2 size
16	associated with the LPA gene may help identify individuals at higher risk of developing PAD
17	and worse outcomes. Given Lp(a) genetic predisposition and low variability of levels throughout
18	lifetime, one measurement may be sufficient and is the standard of care in many European
19	countries <sup>28</sup> .
20	

Further research in larger cohorts is needed to establish a more robust understanding of the
mechanisms and impact of apo(a) isoform size on surgical outcomes in patients PAD.

17

1	Randomized clinical trials to explore potential medical therapy strategies to mitigate associated
2	risks would aid in providing guidelines for perioperative management of these individuals.

3

#### 4 Study Limitations

5 Overall, this was a sample of convenience. Subject samples and prospectively collected data 6 from ongoing biomarker study (ABALEAR) were available to our lipid team to examine 7 additional affecters on surgical outcomes. Although subject baseline characteristics are 8 comparable to larger cohorts, we acknowledge that sample size is small and significantly limit 9 the generalizability of the results. We used firth logistics regression to account for small sample 10 size. Additionally, the cohort is heterogenous in terms of presenting symptoms with surgical 11 interventions geared towards each patient's needs, but ultimately 'no leg is alike,' and the cohort 12 represents a diverse spectrum of lower extremity disease and intervention seen in vascular 13 surgery clinics. Additionally, due to limited size, associations between peripheral interventions 14 and Lp(a) levels/apo(a) size was done without correction for multiple testing.

15

### 16 Conclusion

In this limited cohort, most subjects with chronic symptomatic PAD had elevated Lp(a) levels
without being screened by their medical providers outside of the study, pointing to the need to
increase awareness for Lp(a) screening in vascular patients. Small apo(a) isoform expression
could be an important risk predictor not only for the development of PAD, which has already
been established in literature, but also as a driver of worse short term surgical outcomes. Further
studies identifying the mechanism and relationship of these findings to long-term peripheral

18

- 1 vascular outcomes are warranted, specifically identifying the role of apo(a) size among different
- 2 sexes and races in larger well controlled cohorts.
- 3

## 4 Acknowledgements

- 5 We would like to acknowledge Anastasiya Matveyenko<sup>1</sup> and Srinivas Cherukuri<sup>1</sup> for their
- 6 assistance with study conduction and laboratory measurements. Funding for this study was
- 7 provided by T32HL007343 (M.P.), UL1TR001873 (G.R.S), partial funding for MP stipend and
- 8 manuscript processing funds were supported by a donation from Robin Chemers Neustein to the
- 9 Reyes-Soffer Laboratory.

# 19

# 1 **References**

- 2
- 3 1. Reves-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones 4 DM, Marcovina SM, Yeang C, Koschinsky ML, et al. Lipoprotein(a): A Genetically 5 Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular 6 Disease: A Scientific Statement From the American Heart Association. Arterioscler 7 Thromb Vasc Biol. 2022;42:e48-e60. 8 2. Tomoi Y, Takahara M, Soga Y, Kodama K, Imada K, Hiramori S, Ando K. Impact of High 9 Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy. 10 JACC Cardiovasc Interv. 2022;15:1466-1476. doi: 10.1016/j.jcin.2022.05.050 Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, Kroon J, Hazenberg 11 3. 12 C, de Kleijn DPV. High lipoprotein(a) is associated with major adverse limb events after 13 femoral artery endarterectomy. Atherosclerosis. 2022;349:196-203. doi: 10.1016/j.atherosclerosis.2021.11.019 14 15 4. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69:692-711. doi: 10.1016/j.jacc.2016.11.042 16 17 5. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger 18 S, Oberhollenzer F, et al. Oxidized phospholipids predict the presence and progression 19 of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-20 year prospective results from the Bruneck study. J Am Coll Cardiol. 2006;47:2219-2228. 21 doi: 10.1016/j.jacc.2006.03.001 22 6. Reves-Soffer G, Westerterp M. Beyond Lipoprotein(a) plasma measurements: 23 Lipoprotein(a) and inflammation. *Pharmacol Res.* 2021;169:105689. doi: 24 10.1016/i.phrs.2021.105689 25 Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of 7. 26 lipoprotein (a). J Lipid Res. 2016;57:1339-1359. doi: 10.1194/jlr.R067314 27 Masson W, Lobo M, Barbagelata L, Molinero G, Bluro I, Nogueira JP. Elevated 8. 28 lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic 29 review. Vasc Med. 2022;27:385-391. doi: 10.1177/1358863X221091320 30 9. Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M, 31 Kronenberg F, Mueller T. Increased serum lipoprotein(a) concentrations and low 32 molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem. 2007;53:1298-1305. doi: 33 34 10.1373/clinchem.2007.088013 35 Molgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG. Significant 10. 36 association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb. 1992;12:895-901. doi: 10.1161/01.atv.12.8.895 37 38 11. Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a) 39 level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular 40 outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235:477-482. doi: 41 10.1016/j.atherosclerosis.2014.05.944 42 12. Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, Shafiekhani S, 43 Mohammadi K, Jamialahmadi T, Reiner Z, et al. Effect of Statins on Serum level of hs-44 CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-

1		Analysis of Randomized Controlled Trials. <i>Mediators Inflamm</i> . 2022;2022:8732360. doi:
2	12	10.1155/2022/8/32360 Sanahri 7 Masaumi M. Ehrahimi N. Kiani 7 Nasiri AA. Kahan E. Shaikh Eathallahi M
4	13.	Kazemi Arababadi M. Asadikaram G. Atoryastatin. Losartan and Cantonril Lead to
5		Unregulation of TGE-beta, and Downregulation of IL-6 in Coronary Artery Disease and
6		Hypertension PLoS One 2016:11:e0168312 doi: 10.1371/journal.none.0168312
7	14	Biscetti E Ferraro PM Hiatt WR Angelini E Nardella E Cerchini AL Santoliquido A
8	± ··	Pitocco D. Landolfi R. Elex A. Inflammatory Cytokines Associated With Failure of Lower-
9		Extremity Endovascular Revascularization (LER): A Prospective Study of a Population
10		With Diabetes. <i>Diabetes Care</i> , 2019:42:1939-1945, doi: 10.2337/dc19-0408
11	15.	Tsimikas S. Karwatowska-Prokopczuk E. Gouni-Berthold I. Tardif JC. Baum SJ.
12		Steinhagen-Thiessen E. Shapiro MD. Stroes ES. Moriarty PM. Nordestgaard BG. et al.
13		Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med.
14		2020;382:244-255. doi: 10.1056/NEJMoa1905239
15	16.	Mohammedi K, Pigeyre M, Bosch J, Yusuf S, Gerstein HC. Arm and ankle blood pressure
16		indices, and peripheral artery disease, and mortality: a cohort study. <i>Eur Heart J.</i> 2024.
17		doi: 10.1093/eurheartj/ehae087
18	17.	loannis Kosmidis ECKP, Nicola Sartori Mean and median bias reduction in generalized
19		linear models. Statistics and Computing. 2020;30:43-59. doi:
20		https://doi.org/10.1007/s11222-019-09860-6
21	18.	European Society of Hypertension-European Society of Cardiology Guidelines C. 2003
22		European Society of Hypertension-European Society of Cardiology guidelines for the
23		management of arterial hypertension. <i>J Hypertens</i> . 2003;21:1011-1053. doi:
24		10.1097/00004872-200306000-00001
25	19.	Yap T, Silickas J, Weerakkody R, Lea T, Santhirakumaran G, Bremner L, Diamantopoulos
26		A, Biasi L, Thomas S, Zayed H, et al. Predictors of outcome in diabetic patients
27		undergoing infrapopliteal endovascular revascularization for chronic limb-threatening
28		ischemia. <i>J Vasc Surg</i> . 2022;75:618-624. doi: 10.1016/j.jvs.2021.09.040
29	20.	Giovanetti F, Gargiulo M, Laghi L, D'Addato S, Maioli F, Muccini N, Borghi C, Stella A.
30		Lipoprotein(a) and other serum lipid subfractions influencing primary patency after
31		infrainguinal percutaneous transluminal angioplasty. <i>J Endovasc Ther</i> . 2009;16:389-396.
32	24	
33	21.	Yanaka K, Akahori H, Imanaka I, Miki K, Yoshihara N, Kimura T, Tanaka T, Asakura M,
34 25		Ishihara IVI. Impact of lipoprotein(a) levels on primary patency after endovascular
35		therapy for femoropopiliteal lesions. <i>Heart Vessels</i> . 2023;38:171-176. doi:
30	22	10.1007/S00380-022-02151-7
3/ 20	22.	Fudim IVI, Hopley CVV, Huang Z, Kavanagn S, Rockhold FW, Baumgartner I, Berger JS,
20 20		Blood Brossure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery
10		Disease: The ELICLID Trial Circ Cardiovascular Outcomes III Symptomatic Peripheral Artery
+0 /11		10 1161/CIRCOLITCOMES 120 006512
41 42	23	Arinze N. Farher A. Levin SR. Cheng TW. Jones DW. Patel VI. Ryhin D. Doros G. Siracuse
43	23.	JJ. Perioperative outcomes after lower extremity bypass and peripheral vascular

1		interventions in patients with morbid obesity and superobesity. <i>J Vasc Surg</i> .
2		2020;71:567-574 e564. doi: 10.1016/j.jvs.2019.05.039
3	24.	Dieter RS, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, Einerson J, McBride PE.
4		Lower extremity peripheral arterial disease in hospitalized patients with coronary artery
5		disease. <i>Vasc Med</i> . 2003;8:233-236. doi: 10.1191/1358863x03vm506ra
6	25.	Hishikari K, Hikita H, Nakamura S, Nakagama S, Mizusawa M, Yamamoto T, Doi J, Utsugi
7		Y, Sudo Y, Kimura S, et al. Usefulness of Lipoprotein(a) for Predicting Clinical Outcomes
8		After Endovascular Therapy for Aortoiliac Atherosclerotic Lesions. J Endovasc Ther.
9		2017;24:793-799. doi: 10.1177/1526602817728068
10	26.	Guedon AF, De Freminville JB, Mirault T, Mohamedi N, Rance B, Fournier N, Paul JL,
11		Messas E, Goudot G. Association of Lipoprotein(a) Levels With Incidence of Major
12		Adverse Limb Events. <i>JAMA Netw Open</i> . 2022;5:e2245720. doi:
13		10.1001/jamanetworkopen.2022.45720
14	27.	Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA,
15		Genest J, Gregoire J, Grover SA, et al. 2021 Canadian Cardiovascular Society Guidelines
16		for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in
17		Adults. <i>Can J Cardiol</i> . 2021;37:1129-1150. doi: 10.1016/j.cjca.2021.03.016
18	28.	Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR,
19		Koschinsky M, Lambert G, Mach F, et al. Lipoprotein(a) in atherosclerotic cardiovascular
20		disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
21		<i>Eur Heart J.</i> 2022;43:3925-3946. doi: 10.1093/eurheartj/ehac361
22	29.	Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de
23		Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018
24		AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
25		the Management of Blood Cholesterol: Executive Summary: A Report of the American
26		College of Cardiology/American Heart Association Task Force on Clinical Practice
27	~~	Guidelines. J Am Coll Cardiol. 2019;73:3168-3209. doi: 10.1016/j.jacc.2018.11.002
28	30.	Viney NJ, Yeang C, Yang X, Xia S, Witztum JL, Tsimikas S. Relationship between "LDL-C",
29		estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a)
30		lowering with an antisense oligonucleotide. <i>J Clin Lipidol</i> . 2018;12:702-710. doi:
31	24	10.1016/j.jaci.2018.02.014
3Z	31.	Shiderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference
33 24		BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAIVIA
34 25	22	Caralol. 2019;4:1287-1295. doi: 10.1001/Jamacardio.2019.3780
33 26	52.	Migra S. Lliusta F. American Heart Association Council on F. et al. Lower Extremity
30 27		Nilsra S, Ojueta F, American Heart Association Council on E, et al. Lower Extremity
57 20		Directione: A Scientific Statement From the American Heart Association <i>Circulation</i>
20 20		
40	22	Zuzi, 144.e17 1-e191. dol. 10.1101/CIN.0000000000000000000
<del>4</del> 0 Д1	JJ.	Holleran S. Thomas T. Reves-Soffer G. Relationship of anolinon rotain(a) isoform size
-+- 1-2		with clearance and production of linoprotein(a) in a diverse cohort. I Linid Pes
43		2023·64·100336_doi· 10.1016/i ilr 2023.100336
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43	31. 32. 33.	estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. <i>J Clin Lipidol</i> . 2018;12:702-710. doi: 10.1016/j.jacl.2018.02.014 Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. <i>JAMA</i> <i>Cardiol</i> . 2019;4:1287-1295. doi: 10.1001/jamacardio.2019.3780 Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM, Misra S, Ujueta F, American Heart Association Council on E, et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. <i>Circulation</i> . 2021;144:e171-e191. doi: 10.1161/CIR.00000000000000005 Matveyenko A, Matienzo N, Ginsberg H, Nandakumar R, Seid H, Ramakrishnan R, Holleran S, Thomas T, Reyes-Soffer G. Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort. <i>J Lipid Res</i> . 2023;64:100336. doi: 10.1016/j.jlr.2023.100336

1	34.	Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V,
2		Schonitzer D, Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for
3		coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16:713-719. doi:
4		10.1161/01.atv.16.6.713
5	35.	Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in
6		cardiovascular disease? <i>J Lipid Res</i> . 2016;57:745-757. doi: 10.1194/jlr.R060582
7	36.	Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Jr.,
8		Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel
9		link between lipoproteins and thrombosis. <i>Blood</i> . 2001;98:2980-2987. doi:
10		10.1182/blood.v98.10.2980
11	37.	Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV. Lp(a)
12		(Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease:
13		New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol.
14		2021;41:465-474. doi: 10.1161/ATVBAHA.120.315291
15	38.	Sepehri Z, Masoumi M, Ebrahimi N, Kiani Z, Nasiri AA, Kohan F, Fathollahi MS, Arababadi
16		MK, Asadikaram G. Correction: Atorvastatin, Losartan and Captopril Lead to
17		Upregulation of TGF-beta, and Downregulation of IL-6 in Coronary Artery Disease and
18		Hypertension. <i>PLoS One</i> . 2017;12:e0172404. doi: 10.1371/journal.pone.0172404
19	39.	Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL,
20		Rimm EB, Tsimikas S, et al. Oxidation-specific biomarkers and risk of peripheral artery
21		disease. J Am Coll Cardiol. 2013;61:2169-2179. doi: 10.1016/j.jacc.2013.02.047
22	40.	Patel SM, Bonaca MP, Morrow DA, Palazzolo MG, Jarolim P, Steg PG, Bhatt DL, Storey
23		RF, Sabatine MS, O'Donoghue ML. Lipoprotein(a) and Benefit of Antiplatelet Therapy:
24		Insights From the PEGASUS-TIMI 54 Trial. <i>JACC: Advances</i> . 2023;2. doi:
25		10.1016/j.jacadv.2023.100675
26	41.	Cui K, Yin D, Zhu C, Song W, Wang H, Jia L, Zhang R, Wang H, Cai Z, Feng L, et al. How Do
27		Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable
28		Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After
29		Percutaneous Coronary Intervention? J Am Heart Assoc. 2022;11:e023578. doi:
30		10.1161/JAHA.121.023578
31	42.	Marlys L. Koschinsky AB, Michael B. Boffa, Dave L. Dixon, Keith C. Ferdinand, Samuel S.
32		Gidding, et al. A Focused Update to the 2019 NLA Scientific Statement on Use of
33		Lipoprotein(a) in Clinical Practice. <i>Journal of Clinical Lipidology</i> . 2024.
<b>•</b> •		

1

Characteristic	Study Sample				
Age, y	66.7 ± 9.7				
Range for age	43-79				
BMI, kg/m <sup>2</sup>		28.1 ± 5.3			
Race	Female (N=12	?) Mc	ale (N=13)		
White	5		7		
Black	3		5		
Hispanic	4		1		
Clinical Characteristics, n(%)		I			
Diabetes mellitus		14 (56%)			
Hypertension		21 (84%)			
Hyperlipidemia		20 (80%)			
History CAD		7 (28%)			
Prior coronary event		4 (16%)			
Ever smoker	20 (80%)				
Medical therapy, n(%)					
Statin	19 (76%)				
Beta-blocker	12 (48%)				
DAPT or AP + DOAC	22 (88%)				
DOAC alone	1 (4%)				
AP alone	2 (8%)				
Total cholesterol, mg/dL	159 ± 46.1				
Triglycerides, mg/dL	148 (105, 238)				
HDL-C, mg/dL	39.8 ± 14.0				
Calculated-LDL, mg/dL*	78.7 ± 34.8				
Apo(a) weighted isoform size	$18.4 \pm 4.1$				
	Black	Hispanic	White		
Plasma Lp(a), nmol/L	68.3 (34.0, 304.1)	228.6 (67.0, 333.0)	125.9 (80.1, 191.3)		
Plasma apoB100, mg/dL	167.7 ± 45.1	225.6 ± 83.7	144.3 ± 59.2		

# Table I. Baseline characteristics, lipid, and lipoprotein levels

Legend: ± represents Mean and Standard Deviation; ( ) represents Median and Interquartile Range.

2

\*Calculated LDL-C means reported for N=24, one subject had >400 mg/dL TG levels (Supplemental Table I). Coronary artery disease (CAD); direct oral anticoagulant (DOAC), antiplatelet (AP), dual antiplatelet therapy (DAPT)

Outcome	Sample (N)	Firth Model Estimate (95% CI)	p Value
$\Delta$ Symptoms	25	0.25 (-1.01, 1.50)	p=0.70
Primary patency	23	-2.81 (-5.57, -0.04)	p <0.05*
ΔABI	14	0.30 (-2.43, 3.01)	p=0.84
Re-Intervention	25	-0.53 (-2.59, 1.54)	p=0.07

## Table IIa. Effects of apo(a) wIS on surgical outcomes

### Table IIb. Effects of Lp(a) on surgical outcomes

Outcome	Sample (N)	Firth Model Estimate (95% CI)	p Value
$\Delta$ Symptoms	25	0.17 (-0.89, 1.23)	p=0.75
Primary patency	23	0.32 (-0.68, 1.33)	p=0.53
ΔΑΒΙ	14	0.92 (-1.57, 3.41)	p=0.47
Re-intervention	25	0.13 (-0.89, 1.15)	p=0.80

Legend: PAD: Peripheral Arterial Disease; *wIS*: weighted Isoform Size;  $\Delta$  ABI: change in Ankle Brachial Index;  $\Delta$ Symptoms: change in symptoms, *wIS* and Lp(a) were standardized, \*statistical significance = p < 0.05; Firth model: exponential estimate (95% CI). Available number of subject data for each outcome (N=X) are provided. Complete ABI data is missing in 11 subjects

Marker	PAD Cohort	*Healthy Controls
IL-6 (pg/mL)	3.3±2.5	0.01-11.5 38
IL-18 (pg/mL)	274.2±147.5	80–120 <sup>39</sup>
hs-CRP (mg/dL)	3.6±4.6	<0.3 40
TNFα (pg/mL)	1.4±0.7	0 - 2.2

Table III. Comparison of inflammatory marker levels in Study Subjects and Healthy Controls.

Legend: ± represents Mean and Standard Deviation; IL: Interleukin; CRP: C-reactive protein; TNF: Tumor Necrosis

Factor. Study Cohort N=25. \*Healthy controls from published literature

#### Figure 1. Negative relationship between Lp(a) levels and *wIS*



Legend: Lp(a): Lipoprotein(a); wIS: weighted Isoform Size.

**1 Figure 2.** Apo(a) size distribution by Lp(a) level quartiles (nmol/L)





4 percentages of study subjects and absolute numbers in ().

5

## **1** Supplemental Data

## 2

## 3 Supplemental Table I. Individual Subject Data

Λ
4

Subject	Lp(a)		%		%		
Number	(nmol/L)	Isoform 1	Isoform 1	Isoform 2	Isoform 2	wIS	SRRE
1	300.99	14	8%	25	18%	15.98	В
2	97.10	17	97%	21	3%	17.12	W
3	92.56	20	78%	31	22%	22.42	W
4	3.40	19	82%	30	18%	20.98	В
5	4.12	27	100%			27	В
б	73.82	14	78%	26	22%	16.64	В
7	193.26	18	100%			18	W
8	190.63	13	100%			13	W
9	228.60	18	82%	24	18%	19.08	Н
10	43.91	28	96%	34	4%	28.24	В
11	397.62	17	100%			17	Н
12*	305.28	16	100%			16	W
13	108.34	13	91%	18	9%	13.45	W
14	448.08	17	100%			17	W
15	332.96	14	90%	13	10%	13.9	Н
16	42.62	13	99%	29	1%	13.16	W
17	313.38	17	100%			17	В
18	<2.80	15	100%			15	W
19	63.84	24	100%			24	В
20	42.47	19	84%	24	16%	19	Н
21	156.73	19	100%			19	W
22	67.04	23	100%			23	Н
23	7.05	15	81%	32	19%	18.23	W
24	143.43	21	100%			21	W
25	556.02	14	99%	29	1%	14.15	В

5 6 Legend: wIS – weighted Isoform Size; SRRE – Self Reported Race/Ethnicity. B-Black, W-White, H-Hispanic. Large isoform  $\geq$ 22, Small isoform<22. \*Calculated LDL-C not reported (TG levels >400 mg/dL).

2

# 8 Supplemental Figure 1. Apo(a) weighted isoform sizes in re-operative patients



11 Legend: wIS – weighted Isoform Size, Subject Number (N) underwent re-operation at 3-6 months.

3

#### 13 Supplemental Figure 2. ABALEAR study CONSORT flow diagram



L4 L5

Legend: LE-lower extremity; US-ultrasound; ABI-ankle brachial index; N-sample number